Because of the disease itself or the various treatments they receive, breast cancer patients have poorer immunity and are also among those who are susceptible to the New Coronavirus. So, are breast cancer patients able to receive the neo-coronavirus vaccine?
This is a situation that has to be looked at separately:
I. Conditions that are not suitable for the neostriatal vaccine
1. Patients undergoing chemotherapy
The 2013 Infectious Diseases Society of America (IDSA) Clinical Practice Guidelines for Vaccination in Immunocompromised Individuals recommend that patients receive the vaccine 2 weeks before starting chemotherapy and 3 months after finishing chemotherapy, and that vaccination is not recommended during chemotherapy.
This is because vaccines work by injecting inactivated or attenuated virus into the body to promote active production of immune substances such as antibodies by the body’s immune system. In contrast, most chemotherapy drugs kill cancer cells while also killing the body’s normal tissue cells, immune cells, etc., resulting in a decrease in the function of the patient’s immune system and an inability to effectively produce antibodies.
2. Patients during pregnancy and breastfeeding
Most of the current clinical trials of the Neocon vaccine have not included a large enough sample size of this population, and from a safety perspective, it remains to be seen whether this group of patients is safe to administer the Neocon vaccine. Therefore, it is recommended that patients who are pregnant or breastfeeding should withhold vaccination.
3.
3. Patients with tumors who are receiving immunotherapy
Immune checkpoint inhibitors (such as PD-1 inhibitors) can upregulate T-cell immune function. Vaccination with a new crown vaccine at this time may increase the body’s immune response, leading to an increased probability of immune-related adverse reactions.
II. Situations in which the New Crown vaccine can be administered
Some clinicians believe that inactivated vaccine is recommended for those who are recovering from breast cancer (including during long-term postoperative endocrine therapy or late adjuvant targeted anti-HER2 therapy) and are “priority vaccinees.
Some physicians believe that during anti-HER2-targeted therapy, in view of unclear drug interactions and possible allergic reactions to antibody-based drugs, as well as the treatment time frame for adjuvant therapy, vaccination with the new crown vaccine can be withheld until the completion of adjuvant therapy.
So, in this case, please also communicate with your supervising physician in a timely manner.